Posts tagged Kevin DeGeeter
Ladenburg ups Novavax PT to $3.50 from $2.50

Ladenburg Thalmann raised its price target for Novavax (NASDAQ:NVAX) to $3.50 from $2.50 after the company presented Phase 1/2 data suggesting its NanoFlu vaccine has the potential to be the most potent product for preventing flu, including the Singapore A strain that is expected to be a dominant strain for the 2019-2020 flu season.

Read More
Ladenburg up Novavax to buy

Ladenburg Thalmann upgraded Novavax (NASDAQ:NVAX) to “buy” from “neutral” with a new price target of $1.60 after the company presented encouraging preclinical data from its nanoparticle influenza vaccine, NanoFlu, and outlined a clinical development strategy targeting older adults. The stock closed at 97 cents on Aug. 8.

Read More
Ladenburg starts Molecular Templates at buy

Ladenburg Thalmann initiated coverage of Molecular Templates (NASDAQ:MTEM) with a “buy” rating and $10.00 price target. The stock closed at $5.50 on August 2.

Read More
Ladenburg starts Catalyst at buy

Ladenburg Thalmann initiated coverage of Catalyst Biosciences (NASDAQ:CBIO) with a ‘buy” rating and $11.00 price target. The stock closed at $4.17 on June 5.

Read More
Ladenburg starts Cidara at buy

Ladenburg Thalmann launched coverage of Cidara Therapeutics (NASDAQ:CDTX) with a “buy” rating and $11.25 price target. The stock closed at $6.95 on March 11.

Read More
Ladenburg starts Kindred Biosciences at buy

Ladenburg Thalmann initiated coverage of Kindred Biosciences (NASDAQ:KIN) with a “buy” rating and a $7.50 price target. The stock closed at $5.40 on Monday.

“We view Kindred as an emerging leader in development of new biologic therapies for companion animals, with two potential product launches in 2017,” writes analyst Kevin DeGeeter.

Read More
Ladenburg starts BioTime at buy

Ladenburg Thalmann has initiated coverage of BioTime (NYSE MKT, TASE:BTX) with a “buy” rating and $6 price target. The stock closed at $3.59 on Thursday.

“We view BioTime as roughly halfway through a restructuring designed to unlock shareholder value through separation of non-core assets and accelerated development of the company's cell therapy programs in ophthalmetry, aesthetics and orthopedics,” writes analyst Kevin DeGeeter.

Read More
Ladenburg starts Aviragen Therapeutics at buy

Ladenburg Thalmann has launched coverage of Aviragen Therapeutics (NASDAQ:AVIR) with a “buy” rating and $2.50 price target. The stock closed at $1.60 on Tuesday.

“We view Aviragen as an emerging small molecule antiviral story with important proof-of-concept data from two Phase 2 programs - respiratory syncytial virus (RSV) and rhinovirus (HRV) - expected in the next six months,” writes analyst Kevin DeGeeter.

Read More